BrainChild Bio Raises $116 Million for CNS CAR-T

Evidence Company announcement · Discovery September 8, 2026 · Importance 4/5 · Direction Positive Summary BrainChild Bio raised a $116 million Series A to fund BCB-276, a B7-H3-directed autologous CAR-T therapy administered into cerebrospinal fluid, through the pivotal-intent Phase II ILLUMINATE study in newly diagnosed…